232 related articles for article (PubMed ID: 37938546)
21. Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma.
Satoh T; Tatsuta T; Sugawara S; Hara A; Hosono M
Oncotarget; 2017 Jun; 8(26):42466-42477. PubMed ID: 28476017
[TBL] [Abstract][Full Text] [Related]
22. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
Kuryk L; Haavisto E; Garofalo M; Capasso C; Hirvinen M; Pesonen S; Ranki T; Vassilev L; Cerullo V
Int J Cancer; 2016 Oct; 139(8):1883-93. PubMed ID: 27287512
[TBL] [Abstract][Full Text] [Related]
23. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Moon J; Wistuba II; Vogelzang NJ; Kalemkerian GP; Redman MW; Gandara DR; Kelly K
J Thorac Oncol; 2017 Aug; 12(8):1299-1308. PubMed ID: 28599887
[TBL] [Abstract][Full Text] [Related]
24. Forchlorfenuron and Novel Analogs Cause Cytotoxic Effects in Untreated and Cisplatin-Resistant Malignant Mesothelioma-Derived Cells.
Henzi T; Diep KL; Oberson A; Salicio V; Bochet CG; Schwaller B
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409322
[TBL] [Abstract][Full Text] [Related]
25. Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.
Pinton G; Manente AG; Daga A; Cilli M; Rinaldi M; Nilsson S; Moro L
Mol Cancer; 2014 Oct; 13():227. PubMed ID: 25277603
[TBL] [Abstract][Full Text] [Related]
26. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
[TBL] [Abstract][Full Text] [Related]
27. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Vázquez R; Licandro SA; Astorgues-Xerri L; Lettera E; Panini N; Romano M; Erba E; Ubezio P; Bello E; Libener R; Orecchia S; Grosso F; Riveiro ME; Cvitkovic E; Bekradda M; D'Incalci M; Frapolli R
Int J Cancer; 2017 Jan; 140(1):197-207. PubMed ID: 27594045
[TBL] [Abstract][Full Text] [Related]
28. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
[TBL] [Abstract][Full Text] [Related]
29. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
30. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
31. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
Linton A; Cheng YY; Griggs K; Schedlich L; Kirschner MB; Gattani S; Srikaran S; Chuan-Hao Kao S; McCaughan BC; Klebe S; van Zandwijk N; Reid G
Br J Cancer; 2014 Jan; 110(2):510-9. PubMed ID: 24327015
[TBL] [Abstract][Full Text] [Related]
32. Connective tissue growth factor produced by cancer‑associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma.
Ohara Y; Enomoto A; Tsuyuki Y; Sato K; Iida T; Kobayashi H; Mizutani Y; Miyai Y; Hara A; Mii S; Suzuki J; Yamashita K; Ito F; Motooka Y; Misawa N; Fukui T; Kawaguchi K; Yokoi K; Toyokuni S
Oncol Rep; 2020 Sep; 44(3):838-848. PubMed ID: 32705221
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
[No Abstract] [Full Text] [Related]
34. Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells.
Ries A; Slany A; Pirker C; Mader JC; Mejri D; Mohr T; Schelch K; Flehberger D; Maach N; Hashim M; Hoda MA; Dome B; Krupitza G; Berger W; Gerner C; Holzmann K; Grusch M
Cells; 2023 Aug; 12(15):. PubMed ID: 37566084
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.
Cortes-Dericks L; Froment L; Boesch R; Schmid RA; Karoubi G
BMC Cancer; 2014 Apr; 14():304. PubMed ID: 24884875
[TBL] [Abstract][Full Text] [Related]
36. Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis.
Jean D; Jaurand MC
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060470
[TBL] [Abstract][Full Text] [Related]
37. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
Laszlo V; Valko Z; Ozsvar J; Kovacs I; Garay T; Hoda MA; Klikovits T; Stockhammer P; Aigner C; Gröger M; Klepetko W; Berger W; Grusch M; Tovari J; Waizenegger IC; Dome B; Hegedus B
J Mol Med (Berl); 2019 Feb; 97(2):231-242. PubMed ID: 30539198
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
Abu Lila AS; Kato C; Fukushima M; Huang CL; Wada H; Ishida T
Int J Oncol; 2016 Apr; 48(4):1399-407. PubMed ID: 26847426
[TBL] [Abstract][Full Text] [Related]
39. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
Xu D; Liang SQ; Yang H; Lüthi U; Riether C; Berezowska S; Marti TM; Hall SRR; Bruggmann R; Kocher GJ; Schmid RA; Peng RW
Br J Cancer; 2018 Jul; 119(1):65-75. PubMed ID: 29921948
[TBL] [Abstract][Full Text] [Related]
40. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]